Stem Pharm, Inc news
Dr. Edsel Abud has joined Stem Pharm’s talented team of Advisors. While attending University of California Irvine for his MD and PhD as part of the NIH`s Medical Scientist Training Program (MSTP), Dr. Abud notably developed one of the first methods to generate human microglia from stem cells, showing their functional genomics and how they play a role in health and disease. Dr. Abud was also the first to demonstrate that human microglia can develop and engraft in mouse brains. Edsel is c
Dr. Ryan Gordon has joined the Stem Pharm team as Sr. V.P. of Business Development and Commercialization. Gordon brings to Stem Pharm over 20 years of business, R&D, and operational experience in developing and commercializing innovative biopharmaceutical technologies to revolutionize disease treatment and improve patient outcomes. He has been a valued leader at large companies (3M) and emerging startups (Rion, StemoniX, Rebiotix) where he made significant contributions to the pioneering
Through control of properties such as substrate mechanical stiffness and adhesion ligand presentation, materials can be designed that enable more physiologically relevant extracellular environments and better direct cellular behaviors within 3D models. At Stem Pharm, we are applying these principles to design PEG-based hydrogels for the development of in vitro neural models.
Stem Pharm has been awarded a $1.7 million SBIR grant from the National Institute of Environmental Health Sciences of the National Institutes of Health (NIH) to optimize its induced pluripotent stem cell (iPSC)-derived model of the central nervous system for drug discovery and toxicology applications. Stem Pharm’s model fills a commercial need to accurately reflect the complexity of cell types and important cell-to-cell interactions in the developing brain. It is the most comprehensive
Dr. Murphy presented a webinar at the Agency for Science, Technology and Research entitled "Robust and Scalable Assembly of Human Organoids for Disease Modeling and Discovery."